Search results for "perioperative"

showing 10 items of 332 documents

EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INN…

2016

TPS4133Background: Approximately 10-20% of patients with gastric cancer (GCa) have HER-2 positive tumors. The addition of T to cisplatin/fluoropyrimidine-based CT improved survival in metastatic HE...

OncologyCisplatinCancer Researchmedicine.medical_specialtybusiness.industryImproved survivalCancermedicine.disease03 medical and health sciences0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinePerioperative chemotherapymedicine030211 gastroenterology & hepatologyPertuzumabStomach cancerbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

Multidisciplinary management of gastric and gastroesophageal cancers

2008

Carcinomas of the stomach and gastroesophageal junction are among the five top leading cancer types worldwide. In spite of radical surgical R0 resections being the basis of cure of gastric cancer, surgery alone provides long-term survival in only 30% of patients with advanced International Union Against Cancer (UICC) stages in Western countries because of the high risk of recurrence and metachronous metastases. However, recent large phase-III studies improved the diagnostic and therapeutic options in gastric cancers, indicating a more multidisciplinary management of the disease. Multimodal strategies combining different neoadjuvant and/or adjuvant protocols have clearly improved the gastric…

Oncologymedicine.medical_specialtyPalliative careEsophageal Neoplasmsmedicine.medical_treatmentDiseaseStomach NeoplasmsInternal medicinemedicineAdjuvant therapyHumansCombined Modality TherapyNeoadjuvant therapyChemotherapybusiness.industryGeneral surgeryPalliative CareGastroenterologyCancerGeneral MedicinePerioperativemedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyEditorialChemotherapy AdjuvantEsophagogastric JunctionbusinessWorld Journal of Gastroenterology
researchProduct

Tissue Polypeptide Antigen in Patients with Breast Cancer and Gynecological Cancer

1984

Abstract The serum concentrations of TPA were determined in 67 patients with primary breast cancer, in 70 patients with metastasizing breast carcinoma and in 20 patients with ovarian cancer of stages III and IV (FIGO). Elevated TPA levels (>85 U/L) were found in 54% of patients with primary breast cancer, in 81% of the cases with disseminated disease and in 86% of patients with an ovarian carcinoma stage III. Preoperative TPA values in patients with primary mammary cancer were found to correlate well with tumor size and axillary lymph node involvement. Perioperative course controls in 10 patients exhibited an increase of TPA serum levels. The observation of the patients with metastasizing b…

Oncologymedicine.medical_specialtybusiness.industryTissue Polypeptide AntigenCA 15-3CancerPerioperativemedicine.diseaseBreast cancerOvarian carcinomaInternal medicinemedicineOvarian cancerbusinessBreast carcinoma
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

High flow nasal therapy in perioperative medicine: from operating room to general ward

2018

Abstract Background High flow nasal therapy (HFNT) is a technique in which humidified and heated gas is delivered to the airways through the nose via small nasal prongs at flows that are higher than the rates generally applied during conventional oxygen therapy. The delivered high flow rates combine mixtures of air and oxygen and enable different inspired oxygen fractions ranging from 0.21 to 1. HFNT is increasingly used in critically ill adult patients, especially hypoxemic patients in different clinical settings. Main body Noninvasive ventilation delivers positive pressure (end-expiratory and inspiratory pressures or continuous positive airway pressure) via different external interfaces. …

Operating Roomsmedicine.medical_specialtymedicine.medical_treatmentPositive pressureReviewAcute respiratory failurePerioperative CarePerioperative medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineOxygen therapyAnesthesiologyPatients' RoomsIntubation IntratrachealmedicineHumansIntubationContinuous positive airway pressureAdministration IntranasalHigh flow nasal therapyNosePerioperative medicinebusiness.industryOxygen Inhalation TherapyHumidity030208 emergency & critical care medicineOxygenationAnesthesiology and Pain Medicinemedicine.anatomical_structure030228 respiratory systemlcsh:AnesthesiologyAnesthesiaNasal CavitybusinessNoninvasive ventilationBMC Anesthesiology
researchProduct

The perioperative management of small animals with previously implanted pacemakers undergoing anaesthesia.

2020

Abstract Objective There is little information in the veterinary literature about the perioperative management of small animal patients with previously implanted pacemakers undergoing elective or emergency non-cardiac procedures. The purpose of this article is to review the current literature with regard to human patients, with previously implanted pacemakers, undergoing general anaesthesia. Using this and the current information on pacemakers and anaesthesia in dogs and cats, we provide recommendations for small animal patients in this situation. Databases used Google Scholar, PubMed and CAB Abstracts using and interlinking and narrowing the search terms: “dog”, “cat”, “small animals”, “an…

Pacemaker ArtificialGeneral VeterinaryPerioperative managementbusiness.industryPerioperativeAnesthesia GeneralCat DiseasesIntensive care unitlaw.inventionTransvenous pacingDogslawAnesthesiologyAnesthesiaPerioperative careCatsMedicineAnimalsHumansGeneral anaesthesiaPacemaker PlacementDog DiseasesbusinessImplanted pacemakerVeterinary anaesthesia and analgesia
researchProduct

COX-2 inhibition and pain management: a review summary

2005

Cyclooxygenase-2 selective inhibitors have long been regarded as potent anti-inflammatory drugs for the treatment of arthritis, osteoarthritis and dysmenorrhea. The reports of cardiovascular risk and the subsequent withdrawal of rofecoxib, and recently valdecoxib, has called the therapeutic potential of coxibs into question. Currently, according to the latest decisions of the US Food and Drug Administration and European Medicines Agency, the approval of valdecoxib has been refused for 1 year due to an increased rate of cardiovascular risks and serious skin reactions. There are restrictions concerning the use of all other coxibs. The short-time use of coxibs, however, in anti-inflammatory tr…

Pain modulationmedicine.medical_specialtybusiness.industryImmunologyArthritisPerioperativeOsteoarthritisPain managementmedicine.diseaseValdecoxibFood and drug administrationAnesthesiamedicineImmunology and AllergyIntensive care medicinebusinessRofecoxibmedicine.drugExpert Review of Clinical Immunology
researchProduct

Out-of-the-box pelvic surgery including iliopsoas resection for recurrent gynecological malignancies: Does that make sense? A single-institution case…

2017

Abstract Objective To report morbidity and oncological outcomes in a consecutive series of lateral isolated recurrent gynecological cancer involving the pelvic side wall (PSW) including the iliopsoas muscle. Material and methods We retrospectively evaluated a consecutive series between 6/2013 and 12/2015 of lateral isolated recurrent gynecological malignancies treated with a lateral endopelvic resection (LEPR). LEPR was defined as an en-bloc lateral resection of a pelvic tumor with sidewall muscle, and/or bone, and/or major nerve, and/or major vascular structure. Post-surgical complications, quality of life (QoL) and survivals were computed. Results Seventy-four women with pelvic isolated r…

Pelvic NeoplasmPsoas MusclePostoperative Complications0302 clinical medicineQuality of lifeRetrospective StudieUterine NeoplasmPelvic Neoplasms030212 general & internal medicineIliopsoas resection; Lateral endopelvic resection; Pelvic side wall disease; Recurrent gynecological malignanciesPelvic NeoplasmsPsoas MusclesOvarian NeoplasmsPelvic side wall diseaseGraft Occlusion VascularPeripheral Nervous System DiseasesIliopsoas resectionGeneral MedicineMiddle AgedThrombosisCompartment SyndromeTreatment OutcomeOncology030220 oncology & carcinogenesisUterine NeoplasmsThrombosiFemaleIliopsoasHumanAdultmedicine.medical_specialtyIliopsoas MuscleIliopsoas resection; Lateral endopelvic resection; Pelvic side wall disease; Recurrent gynecological malignancies; Adult; Aged; Compartment Syndromes; Disease-Free Survival; Female; Graft Occlusion Vascular; Humans; Middle Aged; Muscle Skeletal; Neoplasm Recurrence Local; Ovarian Neoplasms; Pelvic Neoplasms; Peripheral Nervous System Diseases; Postoperative Complications; Psoas Muscles; Quality of Life; Retrospective Studies; Thrombosis; Treatment Outcome; Uterine Neoplasms; Surgery; OncologyCompartment SyndromesDisease-Free Survival03 medical and health sciencesmedicineHumansMuscle SkeletalRetrospective StudiesAgedbusiness.industryOvarian NeoplasmThrombosisRetrospective cohort studyPerioperativeRecurrent gynecological malignanciemedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAQuality of LifeLateral endopelvic resectionPelvic tumorSurgeryPostoperative ComplicationRecurrent gynecological malignanciesNeoplasm Recurrence LocalPeripheral Nervous System DiseasebusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.

2014

ObjectiveThe aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.MethodsWe defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.ResultsThe median age was 66 years. A total of 42.9% of the patients had major complications, and a compl…

Pelvic Neoplasmmedicine.medical_specialtySurvivalPrognosimedicine.medical_treatmentendometrial adenocarcinomaGynecologic oncologyAdenocarcinomaFollow-Up StudieRetrospective StudiemedicineHumansEndometrial NeoplasmPelvic NeoplasmsSurvival rateAgedNeoplasm StagingPelvic NeoplasmsRetrospective StudiesAged 80 and overPelvic exenteration recurrent endometrial adenocarcinomaPelvic exenterationbusiness.industryMedicine (all)Endometrial cancerGeneral surgeryObstetrics and GynecologyRecurrent endometrial cancerRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseasePrognosisSurgeryEndometrial Neoplasmspelvic exenterationSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyCohortFemaleMorbidityNeoplasm Recurrence LocalbusinessHumanFollow-Up Studies
researchProduct